Le Lézard
Classified in: Health
Subjects: NPT, EXE, SCZ, AVO

AARP Response to President Trump's Speech on Prescription Drug Prices


WASHINGTON, May 11, 2018 /PRNewswire-USNewswire/ -- AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond released the following statement in response to President Trump's address today on prescription drug prices:  

AARP national logo. (PRNewsfoto/AARP)

"AARP is encouraged that the President is focusing attention on lowering prescription drug prices. Poll after poll shows the vast majority of Americans, across the political spectrum, are demanding action from Congress to address this problem.

"There is no justifiable reason for Americans to pay the highest prescription drug prices in the world. High-priced drugs hurt everyone, and seniors, who on average take 4.5 medications a month, are particularly vulnerable.

"We welcome a broad look across the entire drug supply chain to find ways to help drive down drug prices. AARP also strongly believes that it is critical that any proposals to lower prescription drug costs don't simply shift the costs around in the health care system without addressing the root problem: the prices set by pharmaceutical companies. 

"AARP has long supported a number of proposals that could help lower drug prices. These include allowing the Secretary of Health and Human Services to negotiate lower drug prices on behalf of millions of Medicare beneficiaries, allowing for the safe importation of lower-priced drugs, reducing the length of market exclusivity for high-priced biologic drugs, prohibiting pay-for-delay deals between brand and generic drug companies, and demanding greater transparency in prescription drug pricing.

"On behalf of our 38 million members and their families, AARP looks forward to working with the Administration and Congress to identify and implement workable solutions that will help lower prescription drug prices and their ultimate costs to patients, taxpayers, and the overall health care system."

About AARP
AARP is the nation's largest nonprofit, nonpartisan organization dedicated to empowering people 50 and older to choose how they live as they age. With a nationwide presence and nearly 38 million members, AARP strengthens communities and advocates for what matters most to families: health security, financial stability and personal fulfillment. AARP also produces the nation's largest circulation publications: AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org or follow @AARP and @AARPadvocates on social media.

SOURCE AARP


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: